Candesartan - Isotope Labelled Standards
References
FAQ's
References
- Naka, Takehiko; Nishikawa, Kohei; Kato, Takeshi, Benzimidazole derivatives, their production and use, EP459136B1, Dec 27, 1996, Takeda Chemical Industries, Ltd., Japan (https://patents.google.com/patent/EP0459136A1/en)
- Stenhoff, Helene; Lagerstrom, Per-Olof; Andersen, Cathrine, Determination of candesartan cilexetil, candesartan and a metabolite in human plasma and urine by liquid chromatography and fluorometric detection, Journal of Chromatography B: Biomedical Sciences and Applications, Volume: 731, Issue: 2, Pages: 411-417, 1999 DOI: (10.1016/s0378-4347(99)00247-9)
Frequently Asked Questions
2. What are the analytical methods to identify and characterize Candesartan impurities?
Semi-preparative HPLC and NMR spectroscopy are the analytical methods that help identify and characterize Candesartan impurities.
3. Which analytical method separates the degradation products and process-related impurities of Candesartan from the drug product?
The ultra-performance liquid chromatography is the analytical method that separates the degradation products and process-related impurities of Candesartan from the drug product.
4. Why is it necessary to eliminate nitrosamine impurities from Candesartan drug substance?
Nitrosamine impurities are carcinogenic and affect drug safety. Hence, it is necessary to eliminate nitrosamine impurities from the Candesartan drug substance.
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.